Etelcalcetide
This injectable medication lowers parathyroid hormone levels in people with chronic kidney disease on dialysis by activating a calcium receptor on the parathyroid gland. It helps manage secondary hyperparathyroidism.
الوزن الجزيئي
1048,3000 g/mol
LogP
-10,70
TPSA
618,00 Ų
قاعدة ليبينسكي للخمسة
راسب
المجالات العلاجية
آلية العمل
Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O
InChI
InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1
Molecular Formula
C38H73N21O10S2
HBD / HBA
18 / 17
الروابط القابلة للدوران
36
الذرات الثقيلة
71
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
This injectable medication lowers parathyroid hormone levels in people with chronic kidney disease on dialysis by activating a calcium receptor on the parathyroid gland. It helps manage secondary hyperparathyroidism.
Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.
Yes, Etelcalcetide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545184. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71511839. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="etelcalcetide"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/etelcalcetide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/etelcalcetide/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/etelcalcetide/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="etelcalcetide"></drugfyi-drug>